Physician profile
Mark Byrne
NPI 1962411272
$5,197.52
in general payments reported to CMS, 2019-2025
43 companies · $1,239 in 2025
The $1,239 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $455 · 2020: $251 · 2021: $407 · 2022: $899 · 2023: $782 · 2024: $1,164 · 2025: $1,239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,186.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,185.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $595.20 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Mylan Specialty L.P. | $525.14 | 2019-2024 | Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $511.59 | 2022-2025 | |
| Heartflow, INC. | $458.60 | 2024-2025 | |
| Amgen INC. | $339.16 | 2019-2025 | Evenity, Prolia, Prolia |
| Merck Sharp & Dohme LLC | $310.05 | 2020-2024 | Verquvo, Belsomra, Januvia |
| Glaxosmithkline, LLC. | $305.63 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Abbvie INC. | $215.01 | 2021-2024 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $210.33 | 2022-2025 | Rexulti, Abilify Maintena |
| Boehringer Ingelheim Pharmaceuticals, INC. | $201.90 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $149.36 | 2019-2024 | |
| Pfizer INC. | $112.09 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $106.74 | 2020-2025 | Lokelma, Farxiga |
| Sunovion Pharmaceuticals INC. | $102.76 | 2019 | |
| Abbott Laboratories | $81.43 | 2020-2023 | Freestyle Libre 3 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $64.30 | 2019 | |
| Collegium Pharmaceutical, INC. | $63.23 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $63.18 | 2020-2025 | Austedo Xr |
| Ucb, INC. | $62.40 | 2022-2024 | Briviact |
| E.R. Squibb & Sons, L.L.C. | $57.28 | 2021-2025 | Eliquis |
| Itamar Medical INC | $56.66 | 2025 | Watchpatone |
| Philips North America LLC | $54.43 | 2019-2025 | (8874) Incourage, Vest Therapy Und |
| Viatris Specialty LLC | $52.19 | 2025 | Yupelri |
| Vanda Pharmaceuticals INC. | $45.60 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $44.75 | 2022 | |
| Radius Health, INC. | $39.95 | 2020-2021 | |
| Lundbeck LLC | $36.47 | 2024-2025 | Rexulti |
| Lilly USA, LLC | $33.85 | 2019-2023 | Lyumjev, Jardiance, Baqsimi |
| Medtronic, INC. | $30.20 | 2022-2023 | Venaseal |
| Depuy Synthes Sales INC. | $23.36 | 2025 | Orthovisc |
| Sumitomo Pharma America, INC. | $23.07 | 2023 | Aptiom |
| Neurocrine Biosciences, INC. | $22.38 | 2022 | |
| Dexcom, INC. | $21.66 | 2023 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $21.54 | 2025 | The Cologuard Plus Collection Kit |
| Xeris Pharmaceuticals, INC. | $20.72 | 2022 | |
| Janssen Pharmaceuticals, INC | $19.54 | 2021 | |
| Baxter Healthcare | $18.31 | 2023 | Hillrom - Life 2000 Ventilation System |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.30 | 2021 | |
| Eisai INC. | $17.24 | 2021 | |
| Rgh Enterprises LLC | $17.07 | 2024 | |
| Astellas Pharma US INC | $16.89 | 2022 | |
| Paratek Pharmaceuticals, INC. | $15.96 | 2025 | Nuzyra |
| Sanofi Pasteur INC. | $12.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Byrne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.